A phase II, 20-week, multi-centre, randomised, double-blind, placebo-controlled, parallel group proof of concept study to investigate the efficacy and safety of GSK1605786 for treatment of patients with active Ulcerative Colitis (CCX115393)

Published: 22-11-2011
Last updated: 30-04-2024

Primary: efficacy of GSK1605786 at week 12 following twice daily administration at 500 mg in patients with active ulcerative colitis. Secondary: safety and tolerability, time course of the efficacy of GSK1605786 continued for up to 16 weeks, anti-...

Ethical review	Approved WMO
Status	Will not start
Health condition type	Gastrointestinal inflammatory conditions
Study type	Interventional

Summary

ID

NL-OMON35581

Source
ToetsingOnline

Brief title
CCX115393

Condition

- Gastrointestinal inflammatory conditions

Synonym
ulcerative colitis

Research involving
Human

Sponsors and support

Primary sponsor: GlaxoSmithKline BV
Source(s) of monetary or material Support: GlaxoSmithKline BV

Intervention

Keyword: efficacy, GSK1605786, safety, ulcerative colitis

Outcome measures

Primary outcome

Ordinal response (remission, response, or no response) to treatment as assessed

by the MAYO score at week 12.

Secondary outcome

Adverse events, remission, response, endoscopic remission, time to

withdrawal/rescue medication, quality of life (IBDQ questionnaire), biomarkers,

PK, receptor occupancy, TECK/CCL25 and CCR9 expression.

Study description

Background summary

GSK1605786A is an orally-administered chemokine antagonist which specifically blocks the migration of gut-specific T cells, which selectively home to the intestine.
Ulcerative colitis is a chronic, idiopathic, relapsing inflammatory disorder of the gastrointestinal tract associated with a dysregulated activation of immune cell function. It affects the colon and the rectum with patients experiencing considerable lifestyle disruption and disability including diarrhoea, rectal blood loss, abdominal pain, malnutrition and anaemia. Currently there is no curative medical therapy and many patients ultimately require colectomy.
The purpose of this proof of concept study is to investigate the efficacy and safety of GSK1605786A (500 mg twice daily) administered orally for 16 weeks as compared with placebo in subjects with moderately-to-severely active ulcerative

colitis.

Study objective

Primary: efficacy of GSK1605786 at week 12 following twice daily administration at 500 mg in patients with active ulcerative colitis. Secondary: safety and tolerability, time course of the efficacy of GSK1605786 continued for up to 16 weeks, anti-inflammatory activity (biomarkers), quality of life, PK, CCR9 occupancy, TECK/CCL25 and CCR9 expression in colonic mucosa.

Study design

Multicenter randomized double blind phase II parallel group study.
Randomisation (2:1) to treatment with:
1. GSK1605786A 500 mg twice daily.
2. Placebo.
Treatment duration 16 weeks.
Stratification according to leftsided/extensive disease.
Approx 36 completed patients (45 to be randomized).
Interim analysis after 18 completed patients.
Independent data safety monitoring board.

Intervention

Treatment with GSK1605786A or placebo.

Study burden and risks

Risk: Adverse effects of study medication.
Burden: 11 visits in 20 weeks. Duration 1-6 h.
Sigmoidoscopy (with biopsy) 1-2 x. Blood tests 11x (total approx. 400 ml), pregnancy test (if relevant) 7x, stool investigation 6x, ECG 3x. 1-4 questionnaires (symptom severity and QoL) 5x.
Diary during 16 weeks, daily registration of abdominal symptoms.
Optional SPECT CT scan 2x

Contacts

Public
GlaxoSmithKline BV

Huis ter Heideweg 62
3705 LZ Zeist
NL

Scientific
GlaxoSmithKline BV

Huis ter Heideweg 62
3705 LZ Zeist
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age
Adults (18-64 years)
Elderly (65 years and older)

Inclusion criteria

* Male and female patients 18 years or above with a history of UC for at least 3 months who remain symptomatic despite receiving oral aminosalicylate (with or without topical aminosalicylate) at a dose of >2.4mg/day mesalazine/mesalamine or equivalent for at least 2 weeks.
* At screening: active ulcerative colitis with spread at least 15 cm from the anal verge and MAYO score of 5-10 inclusive.
* Safe contraception for women of childbearing potential.

Exclusion criteria

* Breastfeeding, pregnancy.
* Known coeliac disease, those who follow a gluten-free diet to manage symptoms of suspected coeliac disease and subjects with a positive screening test for celiac disease.
* Known or suspicion of CD, indeterminate colitis, microscopic colitis, ischaemic colitis or radiation-induced colitis.
* Imminent need for surgery for UC.
* Bowel surgery in the past that might interfere with MAYO score.
* Use of prohibited medications (see protocol for details).
* Usual exclusion criteria for biologicals.

* QTc *450 msec (480 msec for those with Bundle Branch Block)

Study design

Design

Study phase:	2
Study type:	Interventional
Intervention model:	Parallel
Allocation:	Randomized controlled trial
Masking:	Double blinded (masking used)
Control:	Placebo
Primary purpose:	Treatment

Recruitment

NL

Recruitment status:	Will not start
Enrollment:	20
Type:	Anticipated

Medical products/devices used

Product type:	Medicine
Brand name:	GSK1605786
Generic name:	GSK1605786

Ethics review

Approved WMO Date:	22-11-2011
Application type:	First submission
Review commission:	METC Amsterdam UMC
Approved WMO Date:	03-01-2012
Application type:	First submission

Review commission:	METC Amsterdam UMC
Approved WMO Date:	13-02-2012
Application type:	Amendment
Review commission:	METC Amsterdam UMC

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
Other	clinicaltrials.gov; registratienummer n.n.b.
EudraCT	EUCTR2011□002818□37-NL
CCMO	NL38666.018.11